| __timestamp | Intra-Cellular Therapies, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 2704597 |
| Thursday, January 1, 2015 | 87718074 | 15470000 |
| Friday, January 1, 2016 | 93831530 | 28037000 |
| Sunday, January 1, 2017 | 79419009 | 71615000 |
| Monday, January 1, 2018 | 132166913 | 99828000 |
| Tuesday, January 1, 2019 | 89124838 | 166023000 |
| Wednesday, January 1, 2020 | 65782137 | 201727000 |
| Friday, January 1, 2021 | 88845513 | 259039000 |
| Saturday, January 1, 2022 | 134715000 | 294781000 |
| Sunday, January 1, 2023 | 180142000 | 344077000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Intra-Cellular Therapies, Inc. and Iovance Biotherapeutics, Inc. have been at the forefront of this race, each investing heavily in research and development (R&D) to bring groundbreaking therapies to market.
From 2014 to 2023, Iovance Biotherapeutics has consistently outpaced Intra-Cellular Therapies in R&D spending. By 2023, Iovance's investment in innovation surged to nearly 344 million, marking a staggering 12,600% increase from its 2014 expenditure. In contrast, Intra-Cellular Therapies increased its R&D spending by approximately 750% over the same period, reaching 180 million in 2023.
This significant investment disparity highlights Iovance's aggressive strategy to lead in the biotech sector. As both companies continue to innovate, their R&D investments will be crucial in shaping the future of medical breakthroughs.
R&D Insights: How Novartis AG and Iovance Biotherapeutics, Inc. Allocate Funds
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: PTC Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.